Chris Schultz Takes On Role As Vice President Of Marketing At Curiteva

Curiteva, Inc., a technology company based in Huntsville, Alabama, has announced the appointment of Chris Schultz as Vice President of Marketing. This strategic move aims to enhance the company's brand and drive innovation and growth. Schultz brings over 17 years of experience in the Spine Industry, having previously worked at Nuvasive, Integrity Implants, and Accelus.

At Nuvasive, Schultz served as a Spine Specialist for ten years before moving into an advanced marketing role with Integrity Implants. Most recently, he was Sr. Director of Product Management at Accelus, where he played a key role in shaping the company's marketing strategy and growth initiatives.

David Schmidt, Chief Commercial Officer at Curiteva, expressed his enthusiasm about Schultz's appointment. "Chris is a talented, experienced leader in our industry, and we are honoured to have him join the Curiteva team," said Schmidt. "His expertise will be instrumental as we continue to innovate and bring new technology to market to meet the evolving needs of our customers and the patients they serve."

Schultz will be responsible for developing and executing strategic marketing plans, building brand awareness, and driving market adoption. He commented on his new role, stating, "Curiteva is poised to set a new bar on how implants are constructed and ultimately received by the patient. The Curiteva brand, its people, core products, and the Inspire Technology have a very bright future and I am honoured and excited to be a part of the team."

Curiteva is a privately held technology and manufacturing company committed to building world-class manufacturing capabilities. The company focuses on accelerating research and development while maintaining lean operational discipline. Curiteva aims to deliver novel technology to meet the evolving needs of its customers and their patients.

The company is pioneering 3D printing of Trabecular PEEK implants with a bioactive nano-surface. This technology aims to improve patient outcomes by accelerating immunomodulation and enhancing healing processes.

Future Prospects

With Schultz's extensive background in clinical, marketing, and leadership roles within the Spine Industry, Curiteva is well-positioned for future growth. His experience will be crucial in driving the company's marketing strategy and expanding its market presence.

For more information about Curiteva and its innovative technologies, visit www.curiteva.com.